Oroidin

Oroidin

SCHEMBL12597862

Nc1nc(/C=C/CNC(=O)c2cc(Br)c(Br)[nH]2)c[nH]1

nearest known ligand 0.65

Full drug profile on Sugi Atlas →

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ KCNA6 P17658 9/20 0.65
▸ KCNA3 P22001 9/20 0.65
▸ KCNA4 P22459 9/20 0.65
▸ KCNA5 P22460 3/20 0.65
▸ NT5E P21589 2/20 0.65
▸ MAP2K1 Q02750 2/20 0.65
▸ KCNA2 P16389 1/20 0.65
▸ DAO P14920 1/20 0.42
▸ SCN9A Q15858 2/20 0.40
▸ SCN3A Q9NY46 2/20 0.40
▸ SCN4A P35499 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Oroidin SCHEMBL28891358 1.00 KCNA6 (0.65) KCNA6KCNA3KCNA4KCNA5NT5E
Oroidin SCHEMBL14536687 1.00 KCNA6 (0.65) KCNA6KCNA3KCNA4KCNA5NT5E
SCHEMBL13036735 0.84 KCNA6 (0.67) KCNA6KCNA3KCNA4KCNA5NT5E
SCHEMBL14114457 0.82 KCNA6 (0.45) KCNA6KCNA3KCNA4KCNA5NT5E
Oroidin SCHEMBL13036750 0.79 KCNA6 (1.00) KCNA6KCNA3KCNA4KCNA5NT5E
Oroidin SCHEMBL13036738 0.79 KCNA6 (1.00) KCNA6KCNA3KCNA4KCNA5NT5E
SCHEMBL12598175 0.79 KCNA6 (0.42) KCNA6KCNA3KCNA4KCNA5NT5E
SCHEMBL12598178 0.77 KCNA6 (0.41) KCNA6KCNA3KCNA4KCNA5NT5E
SCHEMBL12597850 0.74 MAP2K1 (0.47) KCNA6KCNA3KCNA4KCNA5NT5E
Hydrochloric Acid SCHEMBL1518077 0.74 MAP2K1 (0.47) KCNA6KCNA3KCNA4KCNA5NT5E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9422404-B2 2-aminoimidazole-functional silicone compositions and methods of making the same DOW CORNING CORPORATION (US) 2016-08-23 — — US disclosed
US-20160024257-A1 2-Aminoimidazole-Functional Silicone Compositions And Methods Of Making The Same DOW SILICONES CORPORATION 2016-01-28 — — US disclosed
US-9084423-B2 Inhibition of bacterial biofilms with imidazole derivatives NORTH CAROLINA STATE UNIVERSITY (US) 2015-07-21 — — US disclosed
US-20140127273-A1 INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE DERIVATIVES NORTH CAROLINA STATE UNIVERSITY (US) 2014-05-08 — — US disclosed
US-8653124-B2 Inhibition of bacterial biofilms with imidazole derivatives NORTH CAROLINA STATE UNIVERSITY (US) 2014-02-18 — — US disclosed
US-20110150819-A1 INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE DERIVATIVES MELANDER CHRISTIAN 2011-06-23 — — US disclosed
US-7906544-B2 Dentifrices; stents; catheters; grafts NORTH CAROLINA STATE UNIVERSITY (US) 2011-03-15 — — US disclosed
US-7906544-B2 Dentifrices; stents; catheters; grafts NORTH CAROLINA STATE UNIVERSITY (US) 2011-03-15 — — US disclosed
US-20080181923-A1 INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE DERIVATIVES NORTH CAROLINA STATE UNIVERSITY 2008-07-31 — — US disclosed
US-20080181923-A1 INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE DERIVATIVES NORTH CAROLINA STATE UNIVERSITY 2008-07-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080181923-A1 INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE DERIVATIVES O60361, TFPI, BLVRB KCNA6 2338/4885KCNA3 2208/4885KCNA4 3513/4885
US-20110150819-A1 INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE DERIVATIVES O60361, TFPI, BLVRB KCNA6 2338/4885KCNA3 2208/4885KCNA4 3513/4885
US-20140127273-A1 INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE DERIVATIVES O60361, TFPI, BLVRB KCNA6 2338/4885KCNA3 2208/4885KCNA4 3513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback